<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="editorial"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5351569</article-id><article-id pub-id-type="pmid">28086205</article-id><article-id pub-id-type="publisher-id">13925</article-id><article-id pub-id-type="doi">10.18632/oncotarget.13925</article-id><article-categories><subj-group subj-group-type="heading"><subject>Editorial: Neuroscience</subject></subj-group></article-categories><title-group><article-title>Regulation of RIC-3 and of nAChR expression</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ben-David</surname><given-names>Yael</given-names></name></contrib><contrib contrib-type="author"><name><surname>Treinin</surname><given-names>Millet</given-names></name></contrib></contrib-group><aff id="A1"><sup>1</sup> Department of Medical Neurobiology, Hadassah Medical School-Hebrew University, Jerusalem, Israel</aff><author-notes><corresp id="cor1"><bold><italic>Correspondence to:</italic></bold><italic>Millet Treinin,</italic><email>millet.treinin@mail.huji.ac.il</email></corresp></author-notes><pub-date pub-type="collection"><day>24</day><month>1</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>12</day><month>12</month><year>2016</year></pub-date><volume>8</volume><issue>4</issue><fpage>5662</fpage><lpage>5663</lpage><history><date date-type="received"><day>23</day><month>11</month><year>2016</year></date><date date-type="accepted"><day>10</day><month>12</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2017 Ben-David and Treinin</copyright-statement><copyright-year>2017</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/3.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><kwd-group><kwd>RIC-3</kwd><kwd>nicotinic acetylcholine receptors</kwd><kwd>alternative splicing</kwd><kwd>cholinergic anti-inflammatory pathway</kwd><kwd>Neuroscience</kwd></kwd-group></article-meta></front><body><p>The nicotinic acetylcholine receptors (nAChRs) form a large and diverse family of pentameric acetylcholine-gated ion channels which are expressed widely and have diverse roles. The best known nAChR, &#x003b1;1&#x003b2;1&#x003b4;&#x003b5; or &#x003b1;1&#x003b2;1&#x003b4;&#x003b3;, is expressed in skeletal muscle and mediates muscle excitation by motor neurons. In neurons nAChRs have both excitatory and modulatory roles and in non-excitable cells they affect many processes including suppression of pro-inflammatory cytokine release from immune cells [<xref rid="R1" ref-type="bibr">1</xref>]. Moreover, CNS-expressed nAChRs have been implicated in several neurodegenerative diseases including Parkinson&#x02019;s disease, dementia with Lewy bodies, and Alzheimer&#x02019;s disease [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R3" ref-type="bibr">3</xref>].</p><p>Maturation of nAChRs is a complex and inefficient process requiring assistance from multiple cellular factors including RIC-3, a conserved endoplasmic reticulum-resident protein and nAChR-specific chaperone. RIC- 3 was first identified in the nematode <italic>Caenorhabditis elegans</italic> as a positive effector of nAChR maturation. Effects of mammalian RIC-3, however, were shown to be either positive or negative depending on the receptor and the experimental system [<xref rid="R1" ref-type="bibr">1</xref>]. The versatile effects of RIC-3 on co-expressed nAChRs and the diverse roles of nAChRs affected by it suggest that mechanisms regulating RIC-3&#x02019;s function enable regulation of multiple processes involving nAChRs. One mechanism likely to affect RIC- 3 function is alternative splicing, as expression studies identified multiple alternatively spliced RIC-3 isoforms differentially expressed in multiple tissues [<xref rid="R4" ref-type="bibr">4</xref>].</p><p>To better understand effects of RIC-3 splicing on nAChR maturation we analyzed two conserved RIC-3 isoforms: one encoding for the full-length (FL) RIC-3 having two transmembrane domains followed by a coiled-coil domain, and the other encoding for the transmembrane domains only (TM). These two RIC-3 isoforms were examined for their effects on three major neuronal nAChRs (&#x003b1;3&#x003b2;4, &#x003b1;4&#x003b2;2 and &#x003b1;7) using electrophysiological analysis in <italic>Xenopus laevis</italic> oocytes. This analysis showed that the TM isoform lacking the coiled-coil domain is defective for either positive or negative effects of RIC-3 depending on the specific nAChR examined [<xref rid="R5" ref-type="bibr">5</xref>]. Specifically, FL amplified currents through &#x003b1;4&#x003b2;2 at low concentrations and inhibited currents at high concentrations; in contrast, FL inhibited currents through &#x003b1;7 at low or very high concentrations and amplified currents at a high concentration. TM did not amplify currents through &#x003b1;7 nAChR and did not inhibit currents through &#x003b1;4&#x003b2;2 nAChR at any concentration. FL and TM similarly amplified currents through &#x003b1;3&#x003b2;4 at low concentrations and inhibited currents at high concentrations [<xref rid="R5" ref-type="bibr">5</xref>].Together these results are consistent with previous results suggesting that RIC-3 interacts differently with different nAChRs [<xref rid="R6" ref-type="bibr">6</xref>].</p><p>Results from expression analysis show that the two RIC-3 isoforms express in the brain differentially and in immune cells RIC-3 expression and splicing are regulated by inflammatory signals. This regulation of RIC-3 expression and splicing is likely to have functional implications as electrophysiology results, summarized above, show either positive or negative effects of RIC- 3 on nAChR expression, depending on RIC-3 expression level, specific RIC-3 isoform, and specific nAChR [<xref rid="R5" ref-type="bibr">5</xref>].</p><p>Of special interest are effects of RIC-3 expression and splicing on the &#x003b1;7 nAChR. Effects of RIC-3 on this receptor are strongly dependent on RIC-3-to-receptor ratio and on the RIC-3 isoform [<xref rid="R5" ref-type="bibr">5</xref>]. The &#x003b1;7 nAChR is widely expressed, has many functions, and has been implicated in several neurodegenerative diseases [<xref rid="R2" ref-type="bibr">2</xref>, <xref rid="R7" ref-type="bibr">7</xref>]. Among other functions, &#x003b1;7 nAChR mediates the cholinergic anti-inflammatory pathway in immune cells - a pathway enabling suppression of inflammation by the vagus nerve. Our results showing regulation of RIC-3 expression and splicing by inflammatory signals in immune cells suggest, therefore, that regulation of RIC-3 expression and splicing affect &#x003b1;7 nAChR functional expression and thereby inflammatory processes. Indeed, RIC-3 and the &#x003b1;7 nAChR have been implicated in neurodegenerative diseases in which neuroinflammation is known or is likely to have a role [<xref rid="R7" ref-type="bibr">7</xref>,<xref rid="R8" ref-type="bibr">8</xref>]. Future studies, therefore, should examine the role of RIC-3 and of mechanisms regulating its expression and splicing in neuroinflammatory diseases.</p></body><back><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treinin</surname><given-names>M.</given-names></name></person-group><source>Biotechnol J</source><year>2008</year><volume>3</volume><fpage>1539</fpage><lpage>47</lpage><pub-id pub-id-type="pmid">18956371</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaaf</surname><given-names>CP.</given-names></name></person-group><source>Genet Med</source><year>2014</year><volume>16</volume><fpage>649</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">24556925</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dani</surname><given-names>JA</given-names></name><etal/></person-group><source>Annu Rev Pharmacol Toxicol</source><year>2007</year><volume>47</volume><fpage>699</fpage><lpage>729</lpage><pub-id pub-id-type="pmid">17009926</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halevi</surname><given-names>S</given-names></name><etal/></person-group><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>34411</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">12821669</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ben-David</surname><given-names>Y</given-names></name><etal/></person-group><source>Mol Brain</source><year>2016</year><volume>9</volume><fpage>47</fpage><pub-id pub-id-type="pmid">27129882</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen Ben-Ami</surname><given-names>H</given-names></name><etal/></person-group><source>Biochemistry</source><year>2009</year><volume>48</volume><fpage>12329</fpage><lpage>36</lpage><pub-id pub-id-type="pmid">19899809</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Treinin</surname><given-names>M</given-names></name><etal/></person-group><source>Cent Nerv Syst Agents Med Chem</source><year>2016</year></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sudhaman</surname><given-names>S</given-names></name><etal/></person-group><source>J Med Genet</source><year>2016</year><volume>53</volume><fpage>559</fpage><lpage>66</lpage><pub-id pub-id-type="pmid">27055476</pub-id></element-citation></ref></ref-list></back></article>